Atara Biotherapeutics Company Insiders
ATRA Stock | USD 11.47 0.86 8.11% |
Atara Biotherapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Atara Biotherapeutics suggests that vertually all insiders are panicking. Atara Biotherapeutics employs about 165 people. The company is managed by 15 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 11.0 employees per reported executive.
Joseph Newell President Executive Vice President Chief Technical Operations Officer |
Atara Biotherapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-18 | Jill Henrich | Disposed 1000 @ 11.2 | View | ||
2024-08-16 | Pascal Touchon | Disposed 3038 @ 6.63 | View | ||
2024-05-16 | Pascal Touchon | Disposed 3260 @ 15.5 | View | ||
2024-03-04 | Pascal Touchon | Disposed 993 @ 18 | View |
Monitoring Atara Biotherapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Atara |
Atara Biotherapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Atara Biotherapeutics' future performance. Based on our forecasts, it is anticipated that Atara will maintain a workforce of about 170 employees by December 2024.Atara Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5748) % which means that it has lost $0.5748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.1486) %, meaning that it created substantial loss on money invested by shareholders. Atara Biotherapeutics' management efficiency ratios could be used to measure how well Atara Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.92, whereas Return On Tangible Assets are forecasted to decline to (1.75). At present, Atara Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.1 M, whereas Non Current Assets Total are forecasted to decline to about 44.3 M.As of November 22, 2024, Common Stock Shares Outstanding is expected to decline to about 4 M. In addition to that, Net Loss is expected to decline to about (215.7 M)
Atara Biotherapeutics Workforce Comparison
Atara Biotherapeutics is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 700. Atara Biotherapeutics totals roughly 165 in number of employees claiming about 24% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.9) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.62) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.62. Atara Biotherapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atara Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.0588 | 1 | 17 | 45,000 | 183,998 |
2024-03-01 | 1.6667 | 10 | 6 | 4,105,000 | 56,192 |
2023-12-01 | 0.6667 | 4 | 6 | 816,825 | 65,084 |
2023-06-01 | 0.5385 | 14 | 26 | 955,500 | 1,350,001 |
2023-03-01 | 1.1429 | 8 | 7 | 2,473,619 | 76,180 |
2022-06-01 | 1.875 | 15 | 8 | 406,500 | 46,664 |
2022-03-01 | 1.0833 | 13 | 12 | 1,379,714 | 74,885 |
2021-12-01 | 0.2308 | 3 | 13 | 13,500 | 63,566 |
2021-09-01 | 0.2 | 2 | 10 | 65,500 | 46,076 |
2021-06-01 | 1.9 | 19 | 10 | 262,354 | 50,177 |
2021-03-01 | 1.0769 | 14 | 13 | 837,162 | 39,059 |
2020-12-01 | 0.1538 | 2 | 13 | 7,000 | 32,833 |
2020-06-01 | 3.0 | 18 | 6 | 814,750 | 22,942 |
2020-03-01 | 1.8 | 9 | 5 | 842,625 | 20,365 |
2019-06-01 | 0.8947 | 17 | 19 | 472,074 | 43,894 |
2019-03-01 | 0.4423 | 23 | 52 | 413,001 | 344,043 |
2018-12-01 | 0.0833 | 3 | 36 | 4,500 | 87,949 |
2018-09-01 | 0.1282 | 5 | 39 | 31,500 | 271,043 |
2018-06-01 | 0.5682 | 25 | 44 | 460,221 | 187,864 |
2018-03-01 | 0.243 | 26 | 107 | 688,820 | 566,313 |
2017-12-01 | 0.2857 | 8 | 28 | 29,760 | 125,038 |
2017-09-01 | 0.2759 | 8 | 29 | 29,759 | 90,332 |
2017-06-01 | 0.8621 | 25 | 29 | 423,606 | 105,541 |
2017-03-01 | 0.6829 | 28 | 41 | 495,178 | 233,061 |
2016-12-01 | 0.2941 | 10 | 34 | 42,181 | 122,830 |
2016-09-01 | 0.5385 | 14 | 26 | 582,179 | 427,838 |
2016-06-01 | 0.3704 | 10 | 27 | 42,181 | 104,145 |
2016-03-01 | 1.2105 | 23 | 19 | 511,069 | 65,133 |
2015-12-01 | 0.413 | 19 | 46 | 615,773 | 84,216 |
2015-09-01 | 0.2535 | 18 | 71 | 287,399 | 551,076 |
2015-06-01 | 0.3043 | 14 | 46 | 460,182 | 1,290,922 |
2014-12-01 | 1.3913 | 32 | 23 | 9,868,548 | 4,777,273 |
Atara Biotherapeutics Notable Stakeholders
An Atara Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atara Biotherapeutics often face trade-offs trying to please all of them. Atara Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atara Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pascal DVM | CEO President | Profile | |
Joseph Newell | Executive Vice President Chief Technical Operations Officer | Profile | |
Rajani MD | Senior Officer | Profile | |
Eric Hyllengren | Executive Officer | Profile | |
Jakob MD | Ex RD | Profile | |
Kerry Daly | Head Communications | Profile | |
Jill Henrich | Executive Quality | Profile | |
Utpal MBA | Ex CFO | Profile | |
Alex Chapman | Vice Relations | Profile | |
Anhco Nguyen | Executive Officer | Profile | |
Manher MD | Executive Officer | Profile | |
Amie Krause | Chief Officer | Profile | |
Charlene Banard | Chief Officer | Profile | |
Amar Murugan | Executive Officer | Profile | |
Dan Maziasz | Executive Officer | Profile |
About Atara Biotherapeutics Management Performance
The success or failure of an entity such as Atara Biotherapeutics often depends on how effective the management is. Atara Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.67) | (1.75) | |
Return On Capital Employed | (11.86) | (11.26) | |
Return On Assets | (1.67) | (1.75) | |
Return On Equity | 2.78 | 2.92 |
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.
Atara Biotherapeutics Workforce Analysis
Traditionally, organizations such as Atara Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atara Biotherapeutics within its industry.Atara Biotherapeutics Manpower Efficiency
Return on Atara Biotherapeutics Manpower
Revenue Per Employee | 52K | |
Revenue Per Executive | 571.5K | |
Net Loss Per Employee | 1.7M | |
Net Loss Per Executive | 18.4M |
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |